Literature DB >> 8816981

Limited loss of tolerance to islet autoantigens in ICA+ first degree relatives of patients with type I diabetes expressing the HLA dqb1*0602 allele.

R Gianani1, C F Verge, R I Moromisato-Gianani, L Yu, Y J Zhang, A Pugliese, G S Eisenbarth.   

Abstract

The DQB1*0602 allele confers dominant protection from Type I diabetes even among islet cell antibody positive (ICA+) first degree relatives of affected individuals. Lack of progression to diabetes in these subjects, despite ICA positivity, could be explained by a loss of tolerance limited to fewer islet autoantigens than in ICA+ relatives progressing to the disease. To test this hypothesis we have determined autoantibodies by radioassay to three islet autoantigens, glutamic acid decarboxylase (GAD), insulin and the novel neuroendocrine antigen ICA512/IA-2 in 84 HLA-typed ICA+ first degree relatives of patients with Type I diabetes. Among the eleven relatives expressing the 0602 allele (0602+) only two were positive for more than one antibody as determined by radioassay. In contrast, 55/73 ICA+ relatives lacking this allele (non-0602) expressed more than one autoantibody (P < 0.01). The prevalence of antibodies to GAD (GAA) was not significantly different in ICA+ relatives with and without the 0602 allele (7/11 in 0602+ versus 60/73 in non-0602). In contrast, anti-insulin antibodies (IAA) were present in only 2/11 0602+ ICA+ relatives versus 47/70 in non-0602 ICA+ relatives (P < 0.01). Similarly, only one individual carrying the 0602 allele was positive for ICA512 autoantibodies versus 33/70 in the non-0602 group (P < 0.01). These data indicate that even among ICA+ relatives the 0602 allele is associated with a limited immune response to islet antigens and amongst 0602+ relatives this response is mostly directed against GAD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8816981     DOI: 10.1006/jaut.1996.0058

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  5 in total

1.  Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy.

Authors:  Christian Siebold; Bjarke E Hansen; Jessica R Wyer; Karl Harlos; Robert E Esnouf; Arne Svejgaard; John I Bell; Jack L Strominger; E Yvonne Jones; Lars Fugger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

Review 2.  Pathogenic mechanisms in type 1 diabetes: the islet is both target and driver of disease.

Authors:  Kate L Graham; Robyn M Sutherland; Stuart I Mannering; Yuxing Zhao; Jonathan Chee; Balasubramanian Krishnamurthy; Helen E Thomas; Andrew M Lew; Thomas W H Kay
Journal:  Rev Diabet Stud       Date:  2012-12-28

3.  High frequency of abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives identified as part of the Diabetes Prevention Trial--Type 1 Diabetes.

Authors:  C J Greenbaum; G Eisenbarth; M Atkinson; L Yu; S Babu; D Schatz; A Zeidler; T Orban; C Wasserfall; D Cuthbertson; J Krischer
Journal:  Diabetologia       Date:  2004-12-16       Impact factor: 10.122

Review 4.  Benefits and risks of pharmacotherapy for narcolepsy.

Authors:  Merrill M Mitler; Roza Hayduk
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression.

Authors:  Alberto Pugliese; David Boulware; Liping Yu; Sunanda Babu; Andrea K Steck; Dorothy Becker; Henry Rodriguez; Linda DiMeglio; Carmella Evans-Molina; Leonard C Harrison; Desmond Schatz; Jerry P Palmer; Carla Greenbaum; George S Eisenbarth; Jay M Sosenko
Journal:  Diabetes       Date:  2016-01-28       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.